Insulin degludec offers similar glycemic outcomes to insulin glargine U100, along with more straightforward dosing, for people with insulin-treated diabetes crossing time zones, a small study suggests.
Insulin-naïve people with type 2 diabetes initiating the second-generation basal insulins glargine 300 or degludec 100 experience similar improvements in glycated hemoglobin levels, show data from the real-world RESTORE-2 study.
06-27-2021 | ADA 2021 | Conference coverage | News
Use of insulin degludec is associated with a reduced risk for recurrent nocturnal hypoglycemia as measured by hourly plasma glucose among adults with type 1 diabetes, suggest findings from the overnight substudy of the HypoDeg trial.
06-26-2021 | ADA 2021 | Conference coverage | News
Consuming a single shot of fructose prior to exercise is a feasible strategy to reduce the risk for exercise-induced hypoglycemia among men with type 1 diabetes treated with insulin degludec, suggest findings from a proof-of-concept study.